01

Introduction

Compounded GLP-1 products are not FDA-approved and are not pre-reviewed by FDA for safety, effectiveness, or quality. The key questions are the exact active ingredient, dosage form, formulation, dispensing pharmacy, written instructions, and current FDA status.

A familiar drug name alone is not enough to establish equivalence with an approved product.

02

How compounded products differ from approved drugs

FDA-approved semaglutide and tirzepatide products undergo premarket review. Compounded versions do not. FDA states that compounded drugs are not reviewed for safety, effectiveness, or quality before they are marketed, which is why an approved pen label cannot automatically be applied to a compounded product.

FDA: FDA primary material

We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure

LIVE CATALOG

Current telehealth prices and providers

Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.

These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.

Compounded semaglutide injectioncompounded (not FDA-approved)$79 lowest comparablecompounded (not FDA-approved)
19 comparable providersVerified 21 October 2026 to 22 October 2026
Compounded semaglutide injection comparable published pricescompounded (not FDA-approved)
ProviderPublished priceWhat is included
#1 CoreAge Rx$79compounded (not FDA-approved), checked 22 October 2026
a month, paying $948 for 12 months up front
Visit provider Affiliate link · we may earn a commission		Compounded semaglutide injection · Injection · medication includedPrice source · checked 22 October 2026
#2 yourEra$89compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded Semaglutide month-to-month · Weekly subcutaneous injection; month-to-month · medication included
Checked 22 October 2026. Month-to-month semaglutide is $89/mo after a 20% discount the page says is auto-applied. The pre-discount figure on the page is $111.25. No checkout code is printed. Medication is included.
Price source · checked 22 October 2026
#3 SnagRX$99compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded semaglutide injection · Weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026
#4 Oak Longevity$119compounded (not FDA-approved), checked 21 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded GLP-1 · Weekly semaglutide injection · medication included
Homepage still prints GLP-1 treatments for weight loss from $119/mo. The same homepage also says prescription weight loss from $108/mo, and the weight-loss page says programs start at $190/month. Those are not one product price.
Price source · checked 21 October 2026
#5 Strut Health$129compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded Semaglutide Injectable · Once-weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026

Showing the 5 lowest comparable published prices from 19 eligible providers. The complete comparison includes every current catalog row.

Different or incomplete price structures
  • bmiMD: $149/mo effective • $447 prepaid every 3 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
  • bmiMD: $129/mo effective • $774 prepaid every 6 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
  • Curex: $49 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
Plus 12 more non-comparable or incomplete prices in the complete comparison.
Open the complete Semaglutide comparison
Compounded tirzepatide injectioncompounded (not FDA-approved)$129 lowest comparablecompounded (not FDA-approved)
18 comparable providersVerified 21 October 2026 to 22 October 2026
Compounded tirzepatide injection comparable published pricescompounded (not FDA-approved)
ProviderPublished priceWhat is included
#1 CoreAge Rx$129compounded (not FDA-approved), checked 22 October 2026
a month, paying $1,548 for 12 months up front
Visit provider Affiliate link · we may earn a commission		Compounded tirzepatide injection · Injection · medication includedPrice source · checked 22 October 2026
#2 yourEra$129compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded Tirzepatide month-to-month · Weekly subcutaneous injection; month-to-month · medication included
Checked 22 October 2026. Month-to-month tirzepatide is $129/mo after a 20% discount the page says is auto-applied. The pre-discount figure on the page is $161.25. The page does not show the old $99 12-month plan.
Price source · checked 22 October 2026
#3 GobyMeds$133compounded (not FDA-approved), checked 22 October 2026
a month, paying $399 for 3 months up front
Visit provider 		Compounded Tirzepatide Starter Plan · Weekly injection · medication includedPrice source · checked 22 October 2026
#4 SnagRX$149compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Compounded tirzepatide injection · Weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026
#5 Strut Health$149compounded (not FDA-approved), checked 22 October 2026
a month, continuing
Visit provider Affiliate link · we may earn a commission		Tirzepatide injection · Once-weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026

Showing the 5 lowest comparable published prices from 18 eligible providers. The complete comparison includes every current catalog row.

Different or incomplete price structures
  • bmiMD: $229/mo effective • $687 prepaid every 3 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
  • bmiMD: $189/mo effective • $1,134 prepaid every 6 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
  • Curex: $149 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
Plus 13 more non-comparable or incomplete prices in the complete comparison.
Open the complete Tirzepatide comparison

Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.

03

What to verify on the product and prescription

Verify the active ingredient, dosage form, formulation, dispensing pharmacy, prescriber, written instructions, and contact route for an error or reaction. FDA has described dosing errors linked to varying containers and concentrations. This page does not provide vial-volume, syringe-unit, reconstitution, or conversion instructions.

Decision points for Compounded GLP-1s: Pharmacy, Formulation, FDA Status, and Questions to Ask compounded (not FDA-approved)
Decision pointWhat the cited evidence can answer
Exact productConfirm the approved indication, route, and formulation
Outcome evidenceKeep direct trials separate from indirect study comparisons
Practical fitReview safety history, other medicines, follow-up, and access
FDA: FDA primary material FDA: FDA primary material
04

Why formulation and FDA policy matter

FDA has raised concerns about some semaglutide and tirzepatide salt forms and products with added ingredients. Shortage-related compounding policies and bulk-substance decisions can also change. Check current FDA materials before making an approval, quality, availability, or equivalence claim about a specific offer.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
05

Ask verification questions

Verify the active ingredient, formulation, dispensing pharmacy, source documentation, written instructions, and who to contact about an error or reaction.

Comparison boundaries for this topic
QuestionEvidence-based check
Exact productConfirm the approved product, formulation, and labeled indication
EvidenceKeep direct trials separate from indirect comparisons
AccessVerify provider terms and price basis independently
FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
06

Regulatory status changes

Shortage resolution, enforcement discretion, and bulks-list policy are time-sensitive. Recheck FDA sources before publication and before commercial claims.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
07

Do not turn this into a dosing guide

This page excludes vial math, syringe units, reconstitution, dose conversion, and self-switching advice.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
08

What the cited sources establish

FDA distinguishes compounded GLP-1 products from approved drugs because compounded products are not pre-reviewed for safety, effectiveness, or quality. FDA communications also describe variable containers, concentrations, salt forms, additives, and dosing errors. Those facts make formulation identity central rather than a technical footnote.

The strongest documentation is product-level: the prescription, dispensing-pharmacy identity, active ingredient, dosage form, and written instructions attached to the container. That record helps distinguish a clinical symptom question from a formulation or dispensing question. FDA communications can clarify the regulatory context, but they do not convert an unverified offer into an approved product or establish that its concentration and instructions match a pen label.

Marketing language can obscure the facts that matter most. A product can use a familiar ingredient name while differing in dosage form, concentration, container, additives, or instructions. Those details affect what a pharmacist can verify and what a clinician needs to know when assessing a reaction. The appropriate comparison starts with the dispense record and current FDA material, then states plainly where information about the exact preparation is unavailable.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
09

Questions that change the next review

The pharmacy conversation should document the active ingredient, dosage form, formulation, dispensing pharmacy, written instructions, and contact path for a suspected error or reaction. Keeping the prescription and container information together helps the clinical and pharmacy teams resolve a product question without importing instructions from an approved pen.

If the prescription, container, pharmacy record, and written instructions do not identify the same formulation, resolve that discrepancy before using a comparison table or making a safety assumption.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
10

Product details that still need verification

A particular pharmacy's quality, lawful compounding status, and bioequivalence to an approved drug require product-specific verification. This guide excludes vial-volume, syringe-unit, reconstitution, and conversion guidance. If product identity is unclear, the comparison claim should stop there.

Compounded does not mean FDA-approved or bioequivalent. FDA has described errors linked to varying containers and concentrations. FDA shortage and compounding policies can change. A low price does not verify quality or suitability. Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article. The next step is a clinician-led review of the exact product and your situation.

Use the current product label and prompt clinical care for urgent symptoms or medication changes.

FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material FDA: FDA primary material
FAQ

Common questions

What does the evidence show about Compounded GLP-1s: Pharmacy, Formulation, FDA Status, and Questions to Ask?
Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article.
Can I use this as dosing or switching advice?
No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
What should I check before acting?
Check the current product label, the exact formulation, and the plan with the prescribing clinician.
Why are labels named so often?
Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Bottom line

Use evidence to improve the next clinical conversation

Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article. The next step is a clinician-led review of the exact product and your situation.

Already on a semaglutide plan? See which of 19 providers charge less than yours

Starting from scratch? How to get compounded tirzepatide injection online

Providers and coupons

Provider guides for this treatment

Sources

  1. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

  2. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

  3. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

  4. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

  5. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

  6. FDA primary materialFDA · Accessed 28 August 2026

    Primary evidence supporting compounded GLP-1 pharmacy and formulation.

Refresh triggers

  • A new FDA label or Medication Guide
  • A new major clinical-trial publication
  • An ADA or AGA guideline update
  • A material change to the verified provider registry